Prospective, open-label trial of rituximab in childhood systemic lupus erythematosus
- PMID: 17152124
- DOI: 10.1007/s11926-006-0038-y
Prospective, open-label trial of rituximab in childhood systemic lupus erythematosus
Comment on
-
B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus.Arthritis Rheum. 2005 Oct;52(10):3168-74. doi: 10.1002/art.21351. Arthritis Rheum. 2005. PMID: 16200620 Clinical Trial.
Similar articles
-
The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus.J Autoimmun. 2018 Jul;91:45-54. doi: 10.1016/j.jaut.2018.03.003. Epub 2018 Apr 7. J Autoimmun. 2018. PMID: 29636274 Clinical Trial.
-
B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.BioDrugs. 2013 Apr;27(2):85-95. doi: 10.1007/s40259-013-0015-8. BioDrugs. 2013. PMID: 23456653
-
Reprint of: B cell elimination in systemic lupus erythematosus. Clin. Immunol. 146(2) 90-103.Clin Immunol. 2013 Sep;148(3):344-58. doi: 10.1016/j.clim.2013.04.001. Epub 2013 Apr 4. Clin Immunol. 2013. PMID: 23642318
-
The effectiveness and safety of biological therapeutics in juvenile-onset systemic lupus erythematosus (JSLE): a systematic review.Lupus. 2018 Nov;27(13):2135-2145. doi: 10.1177/0961203318804879. Epub 2018 Oct 18. Lupus. 2018. PMID: 30336753
-
[Rituximab in systemic lupus erythematosus. Part II: review of clinical experience].Pol Merkur Lekarski. 2010 Aug;29(170):135-40. Pol Merkur Lekarski. 2010. PMID: 20842830 Review. Polish.
Cited by
-
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.Ann Rheum Dis. 2007 Nov;66 Suppl 3(Suppl 3):iii2-22. doi: 10.1136/ard.2007.081430. Ann Rheum Dis. 2007. PMID: 17934088 Free PMC article. Review. No abstract available.